BlackRock’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$33M Sell
2,405,241
-18,222
-0.8% -$250K ﹤0.01% 2686
2025
Q1
$26.8M Sell
2,423,463
-43,748
-2% -$484K ﹤0.01% 2732
2024
Q4
$26.3M Sell
2,467,211
-30,732
-1% -$327K ﹤0.01% 2829
2024
Q3
$31.7M Buy
2,497,943
+303,993
+14% +$3.86M ﹤0.01% 2711
2024
Q2
$36.8M Buy
2,193,950
+477,137
+28% +$8.01M ﹤0.01% 2555
2024
Q1
$25.8M Sell
1,716,813
-2,491
-0.1% -$37.4K ﹤0.01% 2787
2023
Q4
$25.8M Buy
1,719,304
+521,657
+44% +$7.82M ﹤0.01% 2810
2023
Q3
$16.8M Buy
1,197,647
+99,731
+9% +$1.4M ﹤0.01% 2993
2023
Q2
$11.4M Buy
1,097,916
+813,377
+286% +$8.42M ﹤0.01% 3292
2023
Q1
$2.63M Sell
284,539
-64,731
-19% -$598K ﹤0.01% 3845
2022
Q4
$3.1M Buy
349,270
+4,492
+1% +$39.8K ﹤0.01% 3867
2022
Q3
$2.87M Buy
344,778
+4,366
+1% +$36.3K ﹤0.01% 3930
2022
Q2
$2.79M Sell
340,412
-1,360,364
-80% -$11.1M ﹤0.01% 4008
2022
Q1
$14.8M Sell
1,700,776
-27,318
-2% -$238K ﹤0.01% 3290
2021
Q4
$16.4M Buy
1,728,094
+15,871
+0.9% +$151K ﹤0.01% 3331
2021
Q3
$28.8M Sell
1,712,223
-14,816
-0.9% -$249K ﹤0.01% 2997
2021
Q2
$26.4M Buy
1,727,039
+56,434
+3% +$862K ﹤0.01% 3080
2021
Q1
$32.5M Buy
1,670,605
+141,114
+9% +$2.75M ﹤0.01% 2855
2020
Q4
$27.6M Buy
1,529,491
+43,890
+3% +$791K ﹤0.01% 2776
2020
Q3
$28.7M Buy
1,485,601
+19,796
+1% +$382K ﹤0.01% 2592
2020
Q2
$38.3M Buy
1,465,805
+68,829
+5% +$1.8M ﹤0.01% 2374
2020
Q1
$24.9M Buy
1,396,976
+24,113
+2% +$430K ﹤0.01% 2456
2019
Q4
$45.8M Sell
1,372,863
-22,067
-2% -$736K ﹤0.01% 2394
2019
Q3
$33.2M Buy
1,394,930
+56,377
+4% +$1.34M ﹤0.01% 2508
2019
Q2
$48.1M Buy
1,338,553
+915,970
+217% +$32.9M ﹤0.01% 2318
2019
Q1
$15.6M Buy
422,583
+122,554
+41% +$4.53M ﹤0.01% 2858
2018
Q4
$12.9M Buy
300,029
+197,410
+192% +$8.5M ﹤0.01% 2942
2018
Q3
$4.85M Buy
102,619
+12,829
+14% +$606K ﹤0.01% 3471
2018
Q2
$4.47M Buy
+89,790
New +$4.47M ﹤0.01% 3492